- Home
- VNDA vs SPXX Comparison
VNDA vs SPXX Comparison
Compare VNDA & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- SPXX
- Stock Information
- Founded
- VNDA 2002
- SPXX 2004
- Country
- VNDA United States
- SPXX United States
- Employees
- VNDA N/A
- SPXX N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- VNDA Health Care
- SPXX Finance
- Exchange
- VNDA Nasdaq
- SPXX Nasdaq
- Market Cap
- VNDA 261.7M
- SPXX 313.6M
- IPO Year
- VNDA 2006
- SPXX N/A
- Fundamental
- Price
- VNDA $4.55
- SPXX $16.94
- Analyst Decision
- VNDA Strong Buy
- SPXX
- Analyst Count
- VNDA 3
- SPXX 0
- Target Price
- VNDA $15.33
- SPXX N/A
- AVG Volume (30 Days)
- VNDA 362.5K
- SPXX 51.3K
- Earning Date
- VNDA 07-30-2025
- SPXX 01-01-0001
- Dividend Yield
- VNDA N/A
- SPXX 7.55%
- EPS Growth
- VNDA N/A
- SPXX N/A
- EPS
- VNDA N/A
- SPXX N/A
- Revenue
- VNDA $201,351,000.00
- SPXX N/A
- Revenue This Year
- VNDA $16.86
- SPXX N/A
- Revenue Next Year
- VNDA $39.78
- SPXX N/A
- P/E Ratio
- VNDA N/A
- SPXX N/A
- Revenue Growth
- VNDA 13.37
- SPXX N/A
- 52 Week Low
- VNDA $3.81
- SPXX $13.57
- 52 Week High
- VNDA $6.37
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- VNDA 53.76
- SPXX 43.09
- Support Level
- VNDA $4.49
- SPXX $16.85
- Resistance Level
- VNDA $4.63
- SPXX $17.12
- Average True Range (ATR)
- VNDA 0.14
- SPXX 0.18
- MACD
- VNDA 0.00
- SPXX -0.08
- Stochastic Oscillator
- VNDA 50.00
- SPXX 11.39
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35%-75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.